One comment regarding the upfront payment of $14m received by ISIS from Pfizer for their Excalliard acquisition is that:
It is only a portion of the upfront payment of this acquition and the total amount is not announced.
See below:
While specific financial terms are confidential, Pfizer will provide to Excaliard an upfront payment and contingent payments if certain milestones are achieved.
Isis Pharmaceuticals, Inc. is an equity owner of Excaliard and has granted Excaliard an exclusive worldwide license agreement for the development and commercialization of certain antisense drugs, including EXC 001.
As such, Isis will receive a portion of the upfront and milestone payments paid by Pfizer to Excaliard.
source:http://www.businesswire.com/news/home/20111122005412/en/Pfizer-Acquire-Excaliard-Pharmaceuticals
t/a, page-133
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $81.90M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.9¢ | $133.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 575000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 493695 | 6 |
View Market Depth
| Last trade - 11.43am 01/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |